Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Terrye Mastin

Clinical Nurse Specialist, Adult Health Memphis, TN Nurse Practitioner

NPI 1730110693 CMS profile 782687

5625 Poplar Ave, Memphis, TN 38119

Open in the dashboard

General payments

$34,383

411 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Terrye Mastin of Memphis, TN is reported in the CMS Open Payments database as having received $34,383 across 411 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,485 49
2024 General $1,940 57
2023 General $4,644 100
2022 General $13,535 118
2021 General $12,780 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Terrye Mastin
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Terrye Mastin were reported at $1,485. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Terrye Mastin Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $12,780 $133 $48–$445 $132
2022 $13,535 $163 $57–$526 $149
2023 $4,644 $173 $64–$597 $160
2024 $1,940 $171 $54–$575 $164
2025 $1,485 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $11,690 25 payments
  2. AstraZeneca Pharmaceuticals LP $10,337 67 payments
  3. Genzyme Corporation $5,365 47 payments
  4. Novo Nordisk Inc $1,205 50 payments
  5. AbbVie, Inc. $868 34 payments
  6. GlaxoSmithKline, LLC. $756 37 payments
  7. Actelion Pharmaceuticals US, Inc. $624 26 payments
  8. Amgen Inc. $469 20 payments
  9. Abbott Laboratories $407 10 payments
  10. Mallinckrodt Hospital Products Inc. $398 15 payments
  11. Other $2,264 80 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,825 17 payments
  2. Food and Beverage $11,061 375 payments
  3. Consulting Fee $3,045 3 payments
  4. Travel and Lodging $2,228 12 payments
  5. Education $225 4 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Inflammation And Immunology $11,690 25 payments
  2. BREZTRI $8,095 28 payments
  3. DUPIXENT Immunology $5,879 62 payments
  4. UBRELVY $628 26 payments
  5. UPTRAVI $624 26 payments
  6. RYBELSUS $614 38 payments
  7. AIRSUPRA $604 12 payments
  8. OPSUMIT $600 25 payments
  9. Ozempic $541 38 payments
  10. FARXIGA $466 8 payments
  11. Other $5,750 208 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

1,711

Median for Nurse Practitioner: 389

Drug cost

$261,554

Median for Nurse Practitioner: $21,885

Branded share of claims

19.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 11 $48,612
Ozempic Semaglutide Brand 38 $47,770
Farxiga Dapagliflozin Propanediol Brand 34 $39,384
Mounjaro Tirzepatide Brand 26 $35,690
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 38 $35,659
Jardiance Empagliflozin Brand 11 $15,827
Eliquis Apixaban Brand 13 $10,780
Airsupra Albuterol Sulfate/Budesonide Brand 12 $5,893
Ezetimibe Generic 65 $1,898
Esomeprazole Magnesium Generic 23 $1,490

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$33,392

Medicare's payments for the services billed

Medicare patients

95

Average age 74

Services billed

1,008

55 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
COPD 38%
Diabetes 31%
Ischemic heart disease 29%
Depression 22%
Chronic kidney disease 18%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $353
  • Regeneron Healthcare Solutions, Inc. $32
$384 11 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $279
$279 12 —
Wegovy
  • Novo Nordisk Inc $221
$221 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $141
$141 — —
TEZSPIRE
  • Amgen Inc. $97
  • AstraZeneca Pharmaceuticals LP $37
$134 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

411 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record